Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Work In Process (2022 - 2025)

InMed Pharmaceuticals' Work In Process history spans 4 years, with the latest figure at $569262.0 for Q4 2025.

  • For Q4 2025, Work In Process rose 122.37% year-over-year to $569262.0; the TTM value through Dec 2025 reached $569262.0, up 122.37%, while the annual FY2025 figure was $26695.0, 13.38% down from the prior year.
  • Work In Process reached $569262.0 in Q4 2025 per INM's latest filing, up from $422798.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.7 million in Q2 2022 to a low of $18446.0 in Q3 2024.
  • Average Work In Process over 4 years is $424701.1, with a median of $373256.0 recorded in 2025.
  • Peak YoY movement for Work In Process: plummeted 94.01% in 2024, then soared 2192.09% in 2025.
  • A 4-year view of Work In Process shows it stood at $798813.0 in 2022, then tumbled by 76.59% to $186980.0 in 2023, then skyrocketed by 36.91% to $255992.0 in 2024, then skyrocketed by 122.37% to $569262.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Work In Process are $569262.0 (Q4 2025), $422798.0 (Q3 2025), and $26695.0 (Q2 2025).